Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 1 art units • 2 examiners • 0 of 3 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Teneobio Inc. has 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners and are all located within 1 distinct art unit. The concentration in 1 distinct art unit indicates that the company's biotech filings are being reviewed by a single specialized technical group at the USPTO. This structure often allows for more consistent prosecution across related applications in the Biotechnology & Pharmaceuticals field.
WEIDNER, ADAM M is the busiest examiner for the portfolio, currently managing 2 pending office actions. This accounts for 2 of the 3 pending office actions for the company. The other 1 pending office action is handled by the second distinct examiner. With 3 pending office actions and only 2 distinct examiners in 1 distinct art unit, practitioners have a high level of examiner concentration to manage. This allows for a more focused strategy when addressing the requirements of the 1 distinct art unit. Practitioners should leverage the concentration under WEIDNER, ADAM M to ensure that technical arguments remain consistent across the 2 pending office actions he oversees, while also coordinating with the other distinct examiner in the same art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (67%) |
| Double-patenting + other | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WEIDNER, ADAM M | 2 | 63.5% | +33.8% |
| NATARAJAN, MEERA | 1 | 62.5% | +18.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18473057 | ANTI-CD19 ANTIBODIES AND CAR-T STRUCTURES | WEIDNER, ADAM M | 56d |
| 19239816 | ANTI-CD19 ANTIBODIES AND CAR-T STRUCTURES | WEIDNER, ADAM M | — |
| 18404176 | MULTISPECIFIC HEAVY CHAIN ANTIBODIES BINDING TO CD22 AND CD3 | NATARAJAN, MEERA | — |
| Art Unit | Apps |
|---|---|
| 1675 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19239816 | ANTI-CD19 ANTIBODIES AND CAR-T STRUCTURES | WEIDNER, ADAM M | 1675 | §112 | Final Rejection | — | Pending | Jun 16, 2025 |
| 18404176 | MULTISPECIFIC HEAVY CHAIN ANTIBODIES BINDING TO CD22 AND CD3 | NATARAJAN, MEERA | — | §103§112DP | Non-Final OA | — | Pending | Jan 04, 2024 |
| 18473057 | ANTI-CD19 ANTIBODIES AND CAR-T STRUCTURES | WEIDNER, ADAM M | 1675 | §112 | Final Rejection | 56d | Pending | Sep 22, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial